Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells
Open Access
- 11 December 2018
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Ophthalmology
- Vol. 18 (1), 316
- https://doi.org/10.1186/s12886-018-0978-9
Abstract
BackgroundIngrowth of newly formed blood and lymph vessels (angiogenesis) from the limbus region into the cornea can be treated successfully by subconjunctival application of antiangiogenic agents. Currently, there are several angiogenesis inhibitors from various manufacturers available, such as vascular endothelial growth factor (VEGF) antibodies. The aim of the study was to investigate potential cytotoxic effects of two anti-VEGF agents, ranibizumab (Lucentis (R)) and bevacizumab (Avastin (R)) on the human corneal endothelium.MethodsHuman donor corneas, not suitable for corneal transplantation, were organ-cultured in the presence of either ranibizumab (Lucentis (R)) or bevacizumab (Avastin (R)) at different concentrations (group 1: 250g / ml, group 2: 25g / ml, group 3: 2.5g / ml) for a period of up to 4weeks. Microscopic imaging for endothelial cell counting, detection of morphologic alterations of the endothelium, and molecular biology testing (Enzyme-linked Immunosorbent Assay [ELISA]) for metabolic changes was performed.ResultsBackground-corrected results showed neither a significant lactate dehydrogenase (LDH) change with increasing culturing time nor a significant difference between ranibizumab (Lucentis (R)) and bevacizumab (Avastin (R)) treatment. The endothelial cell density revealed also no statistically significant difference between the two treatment groups with ranibizumab (Lucentis (R)) and bevacizumab (Avastin (R)) at all concentrations tested in this study.ConclusionsIn this study, the anti-angiogenic agents ranibizumab (Lucentis (R)) and bevacizumab (Avastin (R)) demonstrated no cytotoxic effects on the corneal endothelium of human organ-cultured donor corneas over the limited study time period of 4weeks. However, based on the study design (in-vitro) and the limited follow-up period, no conclusions on potential long-term effects can be drawn.Keywords
Funding Information
- Novartis Pharma
This publication has 41 references indexed in Scilit:
- Effects of Subconjunctival Bevacizumab on Corneal NeovascularizationCornea, 2012
- Análisis morfométrico del endotelio corneal tras ranibizumab intravítreo en la degeneración macular asociada a la edadArchivos de la Sociedad Española de Oftalmología, 2010
- Effect of Intravitreal Ranibizumab on Corneal Endothelium in Age-Related Macular DegenerationCornea, 2010
- Effects of Topical and Subconjunctival Bevacizumab in High-Risk Corneal Transplant SurvivalInvestigative Opthalmology & Visual Science, 2010
- Corneal transparency: Genesis, maintenance and dysfunctionBrain Research Bulletin, 2009
- Evaluation of Cytotoxic Effects of Bevacizumab on Human Corneal CellsCornea, 2009
- Effect of Intracameral Bevacizumab Injection on Corneal Endothelium in RabbitsCornea, 2008
- Chancen und Risiken der Anti-VEGF-TherapieKlinische Monatsblätter für Augenheilkunde, 2008
- Corneal avascularity is due to soluble VEGF receptor-1Nature, 2006
- Corneal LymphangiogenesisCornea, 2003